NuVasive, Inc.

NasdaqGS:NUVA 株式レポート

時価総額：US$2.1b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

NuVasive 将来の成長

Future 基準チェック /36

NuVasive利益と収益がそれぞれ年間46.2%と6.7%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に14.3% 44.6%なると予測されています。

主要情報

46.2%

収益成長率

44.56%

EPS成長率

Medical Equipment 収益成長16.1%
収益成長率6.7%
将来の株主資本利益率14.28%
アナリストカバレッジ

Good

最終更新日01 Sep 2023

今後の成長に関する最新情報

Recent updates

分析記事 • Apr 18

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Jan 24

What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?

While NuVasive, Inc. ( NASDAQ:NUVA ) might not be the most widely known stock at the moment, it saw a significant share...
分析記事 • Dec 31

NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price

Key Insights NuVasive's estimated fair value is US$60.8 based on 2 Stage Free Cash Flow to Equity Current share price...
分析記事 • Dec 05

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...
分析記事 • Nov 13

These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Sep 22

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Does the September share price for NuVasive, Inc. ( NASDAQ:NUVA ) reflect what it's really worth? Today, we will...
分析記事 • Sep 01

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...
Seeking Alpha • Aug 17

NuVasive Likely Undervalued, But It's Hard To Find Catalysts

NuVasive modestly exceeded topline expectations for Q2, but core U.S. growth is still soft, particularly when factoring in the above-average growth of the cervical disc business. In a challenging spine care market, NuVasive looks at risk of "drifting", with neither the above-average revenue growth nor strong core margins that med-tech investors often seek. NuVasive isn't beyond hope - the cervical franchise looks strong, Pulse is still a long-term opportunity, and NUVA still has good overall share, but it needs to be more dynamic. The shares are undervalued below the mid-$60s, but the stock badly needs a catalyst to get investors excited about the name again. Valuation alone doesn't move stocks - expensive stocks don't fall just because they're expensive, and cheap stocks don't rise just because investors suddenly decide they're too cheap. In most cases, it requires some sort of driver or catalyst to get investors to reconsider a name, and that's a challenge for NuVasive (NUVA) today. The shares of this spine-focused medical device company do look undervalued today, but they've looked undervalued for a while. Although the shares have slightly outperformed the broader medical device space since my last update and outperformed names like Alphatec (ATEC) and SeaSpine (SPNE) while recently starting to lag Globus (GMED), they still haven't done anything to celebrate over the last five years. NuVasive is salvageable, but the company's management needs to offer more than what is apparent today - investors need to have a reason to believe in growth drivers beyond the cervical portfolio and that long-awaited margin improvement will actually materialize. While this could happen, there's a real risk that "okay, but not great" growth and margins keep a lid on the share price performance at NuVasive. Second Quarter Results - A Little Better On The Topline, But Not Really Great Overall NuVasive's second quarter was, at best, "mixed" and not really the sort of quarter that's going to shift sentiment in a meaningfully positive way. Revenue rose 8% and beat expectations by close to 2%. U.S. spine ("Hardware") revenue rose 3% on improved case volumes, and that was better than the declines at Johnson & Johnson (JNJ) and Stryker (SYK) and on pace with Globus, but with the cervical portfolio growing more than 20%, there's still weakness in the core portfolio. U.S. Surgical revenue rose 6%, with improved Pulse sales offsetting a year-over-year decline in biologics, while international sales rose more than 20% in constant currency. Gross margin declined 120bp to 72.4%, missing by 80bp, and the med-tech sector is still seeing noticeable negative impacts from supply chain issues (components, shipping, et al.). Operating income declined 1%, missing by 3%, and operating margin fell 80bp to 13.1%, missing by more than 30bp. Management basically held the line on guidance, though hitting the full year target of 9% to 11% constant currency growth is going to require acceleration from here. Ongoing post-pandemic normalization and some new product introductions can support that acceleration, but the overall U.S. spine market isn't looking especially robust right now. Waiting For Something To Disrupt The Business (In A Good Way) It's been a long, frustrating wait for real momentum in NuVasive's business, and it does explain, at least in part, why these shares have been a laggard over the longer term (five-year, 10-year, and 15-year comparisons to the sector). Revenue growth over the last 15 years hasn't been bad (around 15% a year), but that growth has slowed considerably in the last five years (to the low single digits). Salesforce defections have been a recurrent problem over the years, and relative to companies like Globus, I think you can argue that NuVasive has under-innovated, and that's taking a toll on core franchises like the lateral interbody fusion business. The company was also certainly slow to recognize the importance of robotics, and with the Pulse robotic system no longer expected to achieve first-in-human use this year, that timeline is slipping further. NuVasive has also struggled to hit even its revised operating margin targets. Where the company once talked about the possibility of 25% or better operating margins (some rivals have achieved high-20%s for margins), more recently the goal has been on the order of 20%, but the company is still well short of that - operating margin was just over 13% in the second quarter, and the most bullish sell-side projections I've seen don't call for 20% margins at any point over the next five years. On the positive side, the company's cervical disc business is growing well, and I still see strong growth potential here, as NuVasive's discs are the only ones clinically proven to produce better outcomes than fusion surgery. I also believe the full Pulse platform (not just the robotic aspect, but the planning, neuromonitoring, imaging, and navigation capabilities) can be a significant growth driver, with an addressable market opportunity of around $1.5B (against expected total revenue of around $1.2B in FY'22).
分析記事 • Aug 11

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Aug 03

NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M

NuVasive press release (NASDAQ:NUVA): Q2 Non-GAAP EPS of $0.47 misses by $0.09. Revenue of $310.5M (+5.3% Y/Y) beats by $4.12M.
Seeking Alpha • Jun 13

NuVasive: Industry Tailwinds More Than Fairly Priced

NuVasive has solid underpinnings as a potentially defensive play, with strengthening platform economics. Industry tailwinds also apply to the company, although it needs an above market growth pattern to adequately reward shareholders. We've priced NUVA at $49–$53 noting the stock may be fully priced at its current levels.
分析記事 • Jun 01

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

In this article we are going to estimate the intrinsic value of NuVasive, Inc. ( NASDAQ:NUVA ) by estimating the...
分析記事 • May 11

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Typically, we'll want...
分析記事 • Apr 20

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Mar 30

At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?

NuVasive, Inc. ( NASDAQ:NUVA ), is not the largest company out there, but it saw a double-digit share price rise of...
Seeking Alpha • Mar 01

NuVasive's Turnaround Story Needs A Boost From Better Results

NuVasive managed a modest beat in Q4'21 and the initial guide for 2022 was okay, but the company needs to start showing clear evidence of market share regrowth. The core technology platform, including X360, is sound and newer opportunities like Simplify and Pulse can add meaningfully to revenue growth, but execution is a key unknown. Weak margins have challenged NuVasive for years, and this remains an important driver of earnings/cash flow and sentiment. NuVasive looks undervalued, but sentiment won't shift until the share losses reverse to share gains and there's evidence of positive operating leverage.
分析記事 • Dec 28

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...
分析記事 • Dec 02

Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?

NuVasive, Inc. ( NASDAQ:NUVA ), might not be a large cap stock, but it saw significant share price movement during...
分析記事 • Nov 11

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
分析記事 • Oct 21

NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of NuVasive, Inc...
分析記事 • Sep 29

Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...
分析記事 • Aug 18

At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?

NuVasive, Inc. ( NASDAQ:NUVA ), is not the largest company out there, but it saw significant share price movement...
Seeking Alpha • Aug 12

NuVasive Still Getting No Love With COVID-19 And Competitive Worries

NuVasive produced its second straight quarter with a double-digit operating income beat, but in-line guidance and fears of renewed COVID-19 lockdowns seem to be weighing on the shares. New product innovation appears to be driving revenue growth, with Modulus and the cervical portfolio performing well, and Pulse about to launch. COVID-19 remains a clear short-term risk, but I believe NuVasive's opportunity to regain share and drive operating leverage is undervalued today.
分析記事 • Jul 27

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Jun 17

Are Investors Undervaluing NuVasive, Inc. (NASDAQ:NUVA) By 21%?

Today we will run through one way of estimating the intrinsic value of NuVasive, Inc. ( NASDAQ:NUVA ) by taking the...
分析記事 • May 30

Some Investors May Be Worried About NuVasive's (NASDAQ:NUVA) Returns On Capital

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
分析記事 • May 12

Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Is Not Excessive At All

The share price of NuVasive, Inc. ( NASDAQ:NUVA ) has increased significantly over the past few years. However, the...
分析記事 • Mar 30

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Mar 09

Is Now The Time To Look At Buying NuVasive, Inc. (NASDAQ:NUVA)?

NuVasive, Inc. ( NASDAQ:NUVA ), might not be a large cap stock, but it received a lot of attention from a substantial...
分析記事 • Feb 16

Need To Know: NuVasive, Inc. (NASDAQ:NUVA) Insiders Have Been Buying Shares

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
分析記事 • Jan 26

A Look At The Fair Value Of NuVasive, Inc. (NASDAQ:NUVA)

How far off is NuVasive, Inc. ( NASDAQ:NUVA ) from its intrinsic value? Using the most recent financial data, we'll...
分析記事 • Jan 05

What Type Of Returns Would NuVasive's(NASDAQ:NUVA) Shareholders Have Earned If They Purchased Their SharesYear Ago?

NuVasive, Inc. ( NASDAQ:NUVA ) shareholders should be happy to see the share price up 11% in the last month. But in...

業績と収益の成長予測

NasdaqGS:NUVA - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20251,452911142898
12/31/20241,3607310723312
12/31/20231,279386321412
6/30/20231,22628-3140N/A
3/31/20231,2192023165N/A
12/31/20221,2024030169N/A
9/30/20221,199-2027160N/A
6/30/20221,174-4044171N/A
3/31/20221,159-3738157N/A
12/31/20211,139-6470182N/A
9/30/20211,129-26103217N/A
6/30/20211,1532122232N/A
3/31/20211,062-50107212N/A
12/31/20201,051-3776186N/A
9/30/20201,069-978188N/A
6/30/20201,065-462175N/A
3/31/20201,1536196216N/A
12/31/20191,16865105235N/A
9/30/20191,14648104229N/A
6/30/20191,12752115235N/A
3/31/20191,1164989207N/A
12/31/20181,10212110219N/A
9/30/20181,08524109209N/A
6/30/20181,0604184187N/A
3/31/20181,0384277185N/A
12/31/20171,0278264177N/A
9/30/20171,0276465179N/A
6/30/20171,0193517123N/A
3/31/201799653N/A127N/A
12/31/201696237N/A158N/A
9/30/201690642N/A137N/A
6/30/201686751N/A154N/A
3/31/201683431N/A120N/A
12/31/201581166N/A89N/A
9/30/201580062N/A67N/A
6/30/201579047N/A102N/A
3/31/201577733N/A118N/A
12/31/2014762-17N/A116N/A
9/30/2014749-18N/A124N/A
6/30/2014728-9N/A113N/A
3/31/2014703-11N/A97N/A
12/31/20136858N/A97N/A
9/30/2013660-1N/A101N/A
6/30/2013639-6N/A97N/A
3/31/20136283N/A114N/A
12/31/20126203N/A130N/A
9/30/2012605-4N/A109N/A

アナリストによる今後の成長予測

収入対貯蓄率: NUVAの予測収益成長率 (年間46.2% ) は 貯蓄率 ( 2.2% ) を上回っています。

収益対市場: NUVAの収益 ( 46.2% ) はUS市場 ( 16.8% ) よりも速いペースで成長すると予測されています。

高成長収益: NUVAの収益は今後 3 年間で 大幅に 増加すると予想されています。

収益対市場: NUVAの収益 ( 6.7% ) US市場 ( 11.7% ) よりも低い成長が予測されています。

高い収益成長: NUVAの収益 ( 6.7% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: NUVAの 自己資本利益率 は、3年後には低くなると予測されています ( 14.3 %)。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2023/09/02 09:12
終値2023/08/31 00:00
収益2023/06/30
年間収益2022/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

NuVasive, Inc. 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。28

アナリスト機関
null nullArgus Research Company
Jeffrey JohnsonBaird
Adam FeinsteinBarclays